Rafael Holdings Inc (RFL)

$1.94 -0.06 (-3.00%)
Market Cap 49.83M
Revenue (ttm) 640,000.00
Net Income (ttm) -34.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,376.56%
Debt to Equity Ratio 0.01
Volume 128,300
Avg Vol 236,968
Day's Range N/A - N/A
Shares Out 24.91M
Stochastic %K 26%
Beta 0.91
Analysts Strong Buy
Price Target N/A

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylat...

Industry: Real Estate Services
Sector: Real Estate
Phone: 212 658 1450
Address:
520 Broad Street, Newark, United States
CYTHboundtoblow
CYTHboundtoblow Jun. 18 at 12:01 AM
$RFL are PRVs about to get more expensive with this new change from FDA?
0 · Reply
Mcwewe
Mcwewe Jun. 17 at 10:03 PM
$RFL this guy is pretty sure. I’m not pretty sure. I’m sure you have no idea
1 · Reply
ButterCall
ButterCall Jun. 17 at 8:10 PM
$RFL Good retracement, like to see closes stay above $1.83
1 · Reply
cappy1
cappy1 Jun. 17 at 7:41 PM
$RFL All Content and Data provided by Third-Parties — Terms of Use Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S 10K WIZARD 2:22 PM ET 6/17/2025 http://archive.fast-edgar.com/20250617/AM2Z6222ZZ22W22Z2FZ32M42T4DNZK22ZX7G Filed on: June 17, 2025 Howard Jonas and family add 110,000 shares at 2.10!
1 · Reply
3obby_Axelrod
3obby_Axelrod Jun. 17 at 6:58 PM
$RFL I bought more here, huge position right now 🤩 I will be very surprised if we wouldn’t be in 5$ by end of this month.
2 · Reply
BioinvestorUSA
BioinvestorUSA Jun. 17 at 6:13 PM
$RFL Good results +speedy review …. FDA Commissioner Dr. Marty Makary unveiled the FDA's new Commissioner's National Priority Voucher program, set to expedite drug approval in the United States. Key highlights: • Review time reduced from 10-12 months to just 1-2 months • Team-based "tumor board style" approach for efficient decision-making • Focus on U.S. national health priorities • Enhanced communication between FDA and drug sponsors
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 17 at 6:08 PM
$RFL brought the IMRX kids to u
1 · Reply
northmark1
northmark1 Jun. 17 at 5:56 PM
$RFL Yup Sounds Like they Got Bad News. RFL May be Circling the Bowl for good this Time.
1 · Reply
InvestwithMEH
InvestwithMEH Jun. 17 at 5:23 PM
$RFL pretty sure they got the read out on friday…so yea. if they dont do a PR this week, its likely sub optimal news
1 · Reply
Biotechnicity
Biotechnicity Jun. 17 at 4:51 PM
$RFL Volume is tumbling back to pre-subscription levels. The price has been declining since the week long subscription push. In other words, when there are no external, modifying factors Ms Market remains unenthusiastic about our chances. Looking for a reentry where Jonas felt comfortable - at about $1.30. GLTAL
1 · Reply
Latest News on RFL
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 11, 2025, 7:00 AM EDT - 6 days ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Jun 4, 2025, 4:01 PM EDT - 13 days ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 20, 2025, 4:01 PM EDT - 4 weeks ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 6 weeks ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 7 weeks ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Apr 24, 2025, 4:15 PM EDT - 7 weeks ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 26, 2025, 6:50 AM EDT - 2 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 5:50 PM EDT - 3 months ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 4 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Dec 11, 2024, 7:00 AM EST - 6 months ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Nov 6, 2024, 7:14 PM EST - 7 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

Oct 2, 2024, 12:00 PM EDT - 9 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 10 months ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 10 months ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 10 months ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Oct 30, 2023, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Mar 14, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Nov 15, 2022, 4:01 PM EST - 2 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Oct 31, 2022, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Sep 28, 2022, 7:00 AM EDT - 2 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 2:14 PM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 14, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

May 24, 2022, 11:04 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 17, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 11, 2022, 4:00 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Jan 21, 2022, 7:00 AM EST - 3 years ago

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 18, 2022, 8:30 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Jan 6, 2022, 8:30 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results

Dec 15, 2021, 4:30 PM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 13, 2021, 8:00 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

CYTHboundtoblow
CYTHboundtoblow Jun. 18 at 12:01 AM
$RFL are PRVs about to get more expensive with this new change from FDA?
0 · Reply
Mcwewe
Mcwewe Jun. 17 at 10:03 PM
$RFL this guy is pretty sure. I’m not pretty sure. I’m sure you have no idea
1 · Reply
ButterCall
ButterCall Jun. 17 at 8:10 PM
$RFL Good retracement, like to see closes stay above $1.83
1 · Reply
cappy1
cappy1 Jun. 17 at 7:41 PM
$RFL All Content and Data provided by Third-Parties — Terms of Use Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S 10K WIZARD 2:22 PM ET 6/17/2025 http://archive.fast-edgar.com/20250617/AM2Z6222ZZ22W22Z2FZ32M42T4DNZK22ZX7G Filed on: June 17, 2025 Howard Jonas and family add 110,000 shares at 2.10!
1 · Reply
3obby_Axelrod
3obby_Axelrod Jun. 17 at 6:58 PM
$RFL I bought more here, huge position right now 🤩 I will be very surprised if we wouldn’t be in 5$ by end of this month.
2 · Reply
BioinvestorUSA
BioinvestorUSA Jun. 17 at 6:13 PM
$RFL Good results +speedy review …. FDA Commissioner Dr. Marty Makary unveiled the FDA's new Commissioner's National Priority Voucher program, set to expedite drug approval in the United States. Key highlights: • Review time reduced from 10-12 months to just 1-2 months • Team-based "tumor board style" approach for efficient decision-making • Focus on U.S. national health priorities • Enhanced communication between FDA and drug sponsors
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 17 at 6:08 PM
$RFL brought the IMRX kids to u
1 · Reply
northmark1
northmark1 Jun. 17 at 5:56 PM
$RFL Yup Sounds Like they Got Bad News. RFL May be Circling the Bowl for good this Time.
1 · Reply
InvestwithMEH
InvestwithMEH Jun. 17 at 5:23 PM
$RFL pretty sure they got the read out on friday…so yea. if they dont do a PR this week, its likely sub optimal news
1 · Reply
Biotechnicity
Biotechnicity Jun. 17 at 4:51 PM
$RFL Volume is tumbling back to pre-subscription levels. The price has been declining since the week long subscription push. In other words, when there are no external, modifying factors Ms Market remains unenthusiastic about our chances. Looking for a reentry where Jonas felt comfortable - at about $1.30. GLTAL
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 17 at 4:10 PM
$RFL AKBA will be going through a shift now with every moving part nuwe etc.
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 17 at 4:10 PM
$RFL have temp built tracks along the 1.7-sub 2 range for u to not just fall and crash randoly for the time being in this particular time frame and window the now
0 · Reply
cryptobythelake
cryptobythelake Jun. 17 at 3:35 PM
$RFL $MDAI Hey LTL how about scrubbing all of your post with trading symbols that are NOT MDAI? After all this IS the MDAI board and bringing other symbols to the table is not providing any clarity to discussions here. Thanks.
3 · Reply
EddieH2020
EddieH2020 Jun. 17 at 3:02 PM
$RFL Why didn’t they drop data yet?
0 · Reply
n3hex
n3hex Jun. 17 at 3:00 PM
$RFL $1.5 before results? what a rollercoaster
0 · Reply
northmark1
northmark1 Jun. 17 at 1:53 PM
$RFL Barely Hanging on....
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 17 at 10:29 AM
$RFL $MDAI gave portions of your move to IMRX for now as few of stocks need to crash sub 0.2 after these u were suppose to be apart of that as we change your destiny's
0 · Reply
Moksi
Moksi Jun. 17 at 4:40 AM
$RFL
0 · Reply
equtz
equtz Jun. 17 at 2:34 AM
$RFL everyone focused on what could go wrong instead of what could go right. Loser mindset. Do you think Howard drops a fresh$20M for a tax loss? No.
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 16 at 10:51 PM
$RFL building extensive steps using many stocks for u for now useg many more atleast 7
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 16 at 9:51 PM
$RFL $MDAI didnt tag XTIA $PSTV ! @joka2189 i just puit out key messages last 30 min ish
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 16 at 9:37 PM
$BDRX U will be called upon due to soo many factors and reasons and $RFL just so many also $ENVB $DNN !
1 · Reply